Swedish Orphan Biovitrum AB (publ)
BIOVF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $823 | $6,175 | $6,465 | $7,436 |
| % Growth | -86.7% | -4.5% | -13.1% | – |
| Cost of Goods Sold | $957 | $1,426 | $1,589 | $1,600 |
| Gross Profit | -$134 | $4,749 | $4,876 | $5,836 |
| % Margin | -16.3% | 76.9% | 75.4% | 78.5% |
| R&D Expenses | $80 | $851 | $834 | $981 |
| G&A Expenses | $0 | $2,019 | $1,776 | $3,190 |
| SG&A Expenses | -$514 | $2,019 | $1,776 | $3,190 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $869 | $908 | $3 |
| Operating Expenses | -$434 | $3,739 | $3,518 | $4,174 |
| Operating Income | $300 | $1,010 | $1,358 | $1,662 |
| % Margin | 36.4% | 16.4% | 21% | 22.4% |
| Other Income/Exp. Net | -$726 | -$216 | -$262 | -$225 |
| Pre-Tax Income | -$426 | $794 | $1,096 | $1,437 |
| Tax Expense | -$120 | $160 | $221 | $47 |
| Net Income | -$307 | $636 | $875 | $1,397 |
| % Margin | -37.2% | 10.3% | 13.5% | 18.8% |
| EPS | -0.89 | 1.85 | 2.55 | 4.07 |
| % Growth | -148.1% | -27.5% | -37.3% | – |
| EPS Diluted | -0.89 | 1.83 | 2.52 | 4.03 |
| Weighted Avg Shares Out | 345 | 344 | 343 | 343 |
| Weighted Avg Shares Out Dil | 345 | 347 | 347 | 347 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $18 | $216 | $262 | $225 |
| Depreciation & Amortization | $796 | $889 | $938 | $932 |
| EBITDA | $387 | $1,899 | $2,296 | $2,593 |
| % Margin | 47% | 30.8% | 35.5% | 34.9% |